Monday, July 15, 2024

Veozah: A New FDA-Approved Non-Hormonal Treatment for Menopausal Hot Flashes Faces Accessibility Challenges

Similar articles

Veozah, a novel treatment for menopausal hot flashes, received FDA approval in May. Distinguished from prior treatments, Veozah is an oral pill taken once daily that does not depend on hormone replacement therapy. Instead, it blocks a chemical that influences the body’s temperature regulation. Clinical trials have demonstrated that Veozah significantly diminishes the frequency and severity of hot flashes.

However, accessibility may present a significant hurdle. Veozah has a monthly list price of $550, resulting in an annual cost of $6,600. While the pharmaceutical company provides patient assistance, it is capped annually at $1,300 and is not available to the public insurance market. Coverage in the commercial market is also currently limited, often with stringent prerequisites.

Although it is too early for a comprehensive analysis, it is noteworthy that many new drugs eventually secure a place on the formulary. The positioning of these drugs, determined by payers based on various factors, is critical. A cost-effectiveness analysis by ICER suggested an ideal yearly price of around $2,000, which is significantly lower than the current price, and could influence payers’ pricing and reimbursement decisions.

Given the varying benefits to different sub-populations, reconsideration of the cost-effectiveness might be necessary. This could potentially lead to more favorable policies for specific patient groups. Despite its proven efficacy in treating menopausal hot flashes, the accessibility and affordability of Veozah remain significant challenges to be addressed.

Despite its proven efficacy in treating menopausal hot flashes, the accessibility and affordability of Veozah remain significant challenges to be addressed. It is crucial to continue monitoring the positioning of new, effective drugs like Veozah on the formulary and their impacts on patients’ access to these treatments. Future developments may involve adjustments in cost-effectiveness analysis, potentially leading to more favorable policies for specific patient groups, making the drug more accessible and affordable for those who need it.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article